Trial Profile
Hepatitis C Virus Infection Induced Insulin Resistance: Different Contribution From Liver and Extrahepatic Sites as Inferred by Treating Chronic Hepatitis C Patients With an Interferon-free Antiviral Combination
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2019
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
- 15 May 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.